Skip to the page

Data / Drug companies / Takeda Pharmaceuticals America, Inc.

Takeda Pharmaceuticals America, Inc.: 32 products in the FDA NDC directory, labeler code 54092

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Takeda Pharmaceuticals America, Inc. (labeler code 54092) lists 32 products in the FDA National Drug Code Directory, covering 9 finished drugs by generic name. By type: 32 prescription drugs. Its main marketing category is new drug applications (NDA). The newest product started marketing on December 14, 2018.

The request: Watch Takeda Pharmaceuticals America, Inc. (FDA labeler code 54092): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
54092
Products in commercial distribution
32
Packages
37
Finished drugs by generic name
9
Prescription products
32
Over the counter products
0
Controlled substance products
Schedule II 10
Flagged as original packager
28 of 28 products that carry the flag
Started marketing in the last 12 months
0
Earliest marketing start
May 10, 1993
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
New drug applications (NDA)2990.6%
Biologics (BLA)26.2%
Authorized generics (NDA)13.1%

Products by type

TypeProductsShare
Prescription drugs32100%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

DrugProductsCompanies listing it
Lanthanum carbonate57
Mesalamine441
Guanfacine433
Carbamazepine352
Prucalopride218
Idursulfase11
Velaglucerase alfa11
Icatibant acetate11
Anagrelide hydrochloride11

Dosage forms

Dosage formProductsShare
Capsule, extended release1340.6%
Tablet, extended release412.5%
Tablet, chewable39.4%
Capsule39.4%
Tablet, delayed release26.2%
Tablet, film coated26.2%
Powder26.2%
Solution, concentrate13.1%
Injection, powder, lyophilized, for solution13.1%
Injection, solution13.1%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Motegrity54092-547Tablet, film coatedNew drug applications (NDA)December 14, 2018
Motegrity54092-546Tablet, film coatedNew drug applications (NDA)December 14, 2018
Mesalamine54092-100Tablet, delayed releaseAuthorized generics (NDA)August 29, 2017
Mydayis54092-477Capsule, extended releaseNew drug applications (NDA)June 20, 2017
Mydayis54092-474Capsule, extended releaseNew drug applications (NDA)June 20, 2017
Mydayis54092-471Capsule, extended releaseNew drug applications (NDA)June 20, 2017
Mydayis54092-468Capsule, extended releaseNew drug applications (NDA)June 20, 2017
Fosrenol54092-257PowderNew drug applications (NDA)September 24, 2014
Fosrenol54092-256PowderNew drug applications (NDA)September 24, 2014
Firazyr54092-702Injection, solutionNew drug applications (NDA)August 25, 2011
Vpriv54092-701Injection, powder, lyophilized, for solutionBiologics (BLA)February 26, 2010
Intuniv54092-519Tablet, extended releaseNew drug applications (NDA)September 2, 2009
Intuniv54092-517Tablet, extended releaseNew drug applications (NDA)September 2, 2009
Intuniv54092-515Tablet, extended releaseNew drug applications (NDA)September 2, 2009
Intuniv54092-513Tablet, extended releaseNew drug applications (NDA)September 2, 2009
Lialda54092-476Tablet, delayed releaseNew drug applications (NDA)January 16, 2007
Elaprase54092-700Solution, concentrateBiologics (BLA)July 24, 2006
Fosrenol54092-254Tablet, chewableNew drug applications (NDA)November 23, 2005
Fosrenol54092-253Tablet, chewableNew drug applications (NDA)November 23, 2005
Fosrenol54092-252Tablet, chewableNew drug applications (NDA)October 26, 2004
Pentasa54092-191CapsuleNew drug applications (NDA)July 8, 2004
Adderall XR54092-389Capsule, extended releaseNew drug applications (NDA)May 22, 2002
Adderall XR54092-385Capsule, extended releaseNew drug applications (NDA)May 22, 2002
Adderall XR54092-381Capsule, extended releaseNew drug applications (NDA)May 22, 2002
Adderall XR54092-391Capsule, extended releaseNew drug applications (NDA)October 11, 2001

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.